2.2.3. Inflammatory Markers Study 2

Significant differences were detected between the four groups for post intervention inflammatory markers using the corresponding baseline value as a covariate (Tables 7 and 8).


**Table 7.** Inflammatory markers baseline, post 6 or 12 weeks, and change data after placebo or SXRG (Study 2).

Data are presented as median (25th and 75th percentile). AA = Placebo for 6 weeks; AB = Placebo for 6 weeks then SXRG treatment for 6 weeks; BB = SXRG treatment for 6 weeks; BA = SXRG treatment for 6 weeks then placebo for 6 weeks. Change determined by median post value (6 or 12 weeks) minus median baseline value. \* *p*-value at baseline determined by T-test on normal, log-transformed (§), square root-transformed data (‡), or Wilcoxon signed rank test (¥) between the two baseline regime groups. *p*-value for post measure determined by ANCOVA using absolute data from 6 weeks (for placebo and active group) and 12 weeks (for placebo then active group and active then placebo group) using baseline data as a covariate. Values with different superscript letters denotes statistical significance (*p* < 0.05).

There were multiple significant changes in specific inflammatory markers, but not in CRP, bearing in mind that CRP was lower at baseline in Study 2.


**Table 8.** Significant correlations with baseline measures and gut microbiota genera in Study 2.


**Table 8.** *Cont.*
